Hydrolysates made of plant extracts and antibacterial agent containing the same

Abstract

The present invention relates to an antibacterial agent and a hydrolysate made of at least one extract that has been produced by extraction using ethanol/water from dried plant material of: a) at least one of the plants selected from the group consisting of: Verbena officinalis L., Sambucus nigra L., Primula veris L., Primula elatior (L.) Hill, and Gentiana lutea L.; and a mixture thereof; or b) a mixture of: Verbena officinalis L., Sambucus nigra L., Primula veris L., Gentiana lutea L., and Rumicis herba ; and subsequent removal of the ethanol/water extraction agent, wherein the hydrolysate can be obtained from the extract via hydrolytic treatment using a mineral acid. The hydrolyzates according to the invention show a pronounced antibacterial effect against germs relevant to the skin, ears, nose, and throat and respiratory systems.

1 . A hydrolysate made of at least one extract, which is produced by:
 extraction using ethanol/water from dried plant material selected from:   a) one or more of the plants selected from the group consisting of:  Verbena officinalis  L.,  Sambucus nigra  L.,  Primula veris  L.,  Primula elatior  (L.) Hill and  Gentian lutea  L.; or   b) a mixture of:  Verbena officinalis  L.,  Sambucus nigra  L.,  Primula veris  L.,  Gentiana lutea  L. and  Rumicis herba;      subsequent removal of the ethanol/water extraction agent, and   hydrolytic treatment of the extract using a mineral acid.   
     
     
         2 . The hydrolysate according to  claim 1 , wherein the extract is produced from the plant material using an extraction agent made of 50% by volume ethanol and 50% by volume water over 6 hours to 36 hours, while stirring and subsequently vacuum evaporating the solvent. 
     
     
         3 . The hydrolysate according to  claim 1 , wherein the hydrolysate is obtained by the hydrolytic treatment of the plant extracts with hydrochloric acid as the mineral acid having a concentration of 1 M to 10 M at 80° C. to 100° C. for 30 minutes to 120 minutes. 
     
     
         4 . The hydrolysate according to  claim 3 , wherein the hydrolytic treatment of the extracts is carried out in the presence of ethanol or ethanol diluted with water. 
     
     
         5 . A hydrolysate according to  claim 1 , wherein the hydrolysate is evaporated to dryness for producing a dry extract and optionally neutralized. 
     
     
         6 . A hydrolysate according to  claim 1 , wherein the plant material for producing the dry extract stems from the following plant components:
 a)  Rumicis herba  ( Rumex acetosa  L.,  Rumex acetosella  L.,  Rumex obtusifolius  L.,  Rumex patientia  L. and  Rumex crispus  I.): leaves and stems;   b)  Verbena officinalis : leaves and upper stem sections;   c)  Sambucus nigra : blossoms;   d)  Primula veris  and/or  Primula eliator : blossoms and capsules; and   e)  Gentiana lutea : roots.   
     
     
         7 . The hydrolysate according to  claim 6 , wherein the dry extract comprises a mixture of  Gentiana lutea : roots,  Rumicis herba : leaves and stems,  Verbena officinalis : leaves and upper stem sections,  Sambucus nigra : blossoms, and  Primula veris : blossoms and capsules, wherein the individual drugs are present in a mass ratio of 1:1:1:1:1 to 1:3:3:3:3. 
     
     
         8 . A hydrolysate according to  claim 1 , wherein the hydrolysate exhibits an antibacterial effect. 
     
     
         9 . The hydrolysate according to  claim 8 , wherein the antibacterial effect is directed against skin, ENT and respiratory tract relevant bacteria and optionally wherein the bacteria are gram positive cocci,  Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans , and/or gram negative rod bacteria, optionally  Haemophilus influenzae.    
     
     
         10 . The hydrolysate according to  claim 9 , wherein the bacteria are selected from the group consisting of  Staphylococcus aureus  (ATCC 25923),  Staphylococcus epidermidis  (ATCC 12228),  Streptococcus pneumoniae  (DSMZ 20566),  Streptococcus pyogenes  (DSMZ 20565),  Haemophilus influenzae  (DSMZ 4690);  Enterococcus casseliflavus  (DSMZ 20680);  Pseudomonas aeruginosa  (ATCC 27853);  Klebsiella pneumoniae  (ATCC 13883);  E. coli; Enterococcus faecalis ; and mixtures thereof. 
     
     
         11 . A hydrolysate according to  claim 1 , wherein it is effective for the protection and/or treatment of infections orally or topically on the skin and mucous membranes and is in the form of a galenic formulation. 
     
     
         12 . An oral formulation comprising the hydrolysate according to  claim 11 , wherein the oral formulation is in the form of sugar-coated tablets, tablets, film-coated tablets, capsules, liquid dilutions, drops, oral solutions or syrups. 
     
     
         13 . An article used for topical applications comprising the hydrolysate according to  claim 11 , wherein the article is a spray, ointment, emulsion, powder, liquid or solid preparation for inhalation, compress, wound and gum dressing, tamponade, tonsil brush solution, gargling solution, or rinsing solution for the nose and ears 
     
     
         14 . A tamponade used for dental applications, further comprising the hydrolysate according to  claim 11 . 
     
     
         15 . The article according to  claim 13 , wherein the rinsing solutions for the nose and ears are present in combination with physiological or hyperosmolar concentrations of salts or salt mixtures. 
     
     
         16 . The hydrolysate according to  claim 1 , wherein the hydrolysate is in the form of a lyophilisate. 
     
     
         17 . An antibacterial agent comprising a hydrolysate according to  claim 1 . 
     
     
         18 . The antibacterial agent according to  claim 17 , wherein the antibacterial agent further comprises pharmaceutically common adjuvants. 
     
     
         19 . A retard formulation comprising the antibacterial agent according to  claim 17 . 
     
     
         20 . An oral formulation comprising the hydrolysate according to  claim 11 , wherein the oral formulation is in the form of drops, oral solutions or syrups.